Video

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Ticiana Leal, MD, associate professor, director, Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, Emory University School of Medicine, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer (NSCLC).

Traditionally, patients with EGFR exon 20 insertion mutations are administered platinum-based chemotherapy as frontline treatment, although they frequently will go on experience disease progression, according to Leal. TKIs such as erlotinib (Tarceva), afatinib (Gilotrif), and gefitinib (Iressa) have demonstrated limited efficacy in this patient population, Leal says. As such, this population of patients often experience poor outcomes and prognoses.

However, key developments, such as the May 2021 FDA approval of amivantamab-vmjw (Rybrevant), an EGFR-MET bispecific antibody, has served to provide patients with NSCLC who harbor EGFR exon 20 mutations with another treatment option, Leal explains. The regulatory decision was based on findings from the phase 1 CHRYSALIS trial (NCT02609776), Leal concludes. 

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.